Foolish End Users, Tricky Integrators - What To Do?

I've seen this sad story play out far too many times. Take a foolish end user, someone both naive and hopeful enough to believe that something impossible works. Combine that with an unscrupulous integrator who pushes science fiction solutions to differentiate himself from the pack and win the deal.

The end user organization ultimately loses when the solution does not work. Good integrators also lose as the foolish end user, at first, thinks that they must not be good nor smart enough as the trickster.

Has this been a problem for you? What do you think can be done to minimize this?

When we criticize marketing campaigns, that is one of our objectives - to help educate or at least warn the broader public to misleading and harmful claims. Additionally, we could start promoting IPVM certified individuals to the broader end user community to help 'regular' end users be aware of credentialed, properly trained individuals. What else can we do? What else do you want to see done?

Login to read this IPVM discussion.
Why do I need to log in?
IPVM conducts unique testing and research funded by member's payments enabling us to offer the most independent, accurate and in-depth information.

**** ***** ** ****** ** **** ******** ** ******* ** end ****'* ********** ****. ** **** ******** ** ***** ** price **** **** ***********, *** *** *** ********, **** ** such ******** **** *** ****. ***** ******** ******** *** ***** is ****** ** **********' ****. *** ** *** **** ** will ** ***** ******* ** *** ******* ***'* ****. **** without ****** **** ************* ****, *** ** *** **** **** passing ******* *** ****** ** *** ******* (***** ********), *** specific ******* ******** ** *** **** ** *** ********* **** be ******** ** ***** ******** ** ***** *********, *** **** them *** **************** **** ** ****. ** * ****...

***********, ****** *** *** ********. ** ****** *** ***** **** of *** *****.

**** *** *****, **** ***** *******, **** ***** ***** ******* on ******* ******* *******.

***** *** *****, **** ***** *******, **** ** '***** **** and ***** *******' ****** ******* **** *** **********, **** ** meet ******** ***** *** **** ****** ** ***** ******. **** raises *** ******** - **** ** ** ** ** **** scenario?

*** **** *** ** ** **** *** ****** ** ********* the ******** ***** ** ***** *********** **** ***, *** ** you ****** **********, **** ***** ** *******...*****! ***'* *** ** by ***...

* **** ***** **** * ******'* ********** ** *** **** where *** ********** ********* * ****** ** ******** ********* **** were ****** **** ****** ** ******** ******** ****. ***** *** project ****** ** ********. * ***** **** *** ********** *** admitted **** **** ****** ** **** *** ****** ** ******* new ********* ****** **** **** *** ****. * ** *** sure **** ***** **** ******** * **** ******* *** *** client ** *** ********* *********** ** ** *** ***** *******. There ***** ** ** * ******* ******* *** ******** *** proven ********. ** ************* **** ** ** **** ** ***** new ************ ** * **** ***** ***********?

******, ********* ******* *** ********.

* **** ******* ******* **** ***********. ** **** **** *** ocassion, * **** ****** **** * ********** *** ****'* * new ******* **** ** *** ******* ****** *** *** ******* when ** ***** **** *** (*.*., "**'* ********* *** * months **** ***"). ****'* ********* *** ***** ** * **** amount ** ****.

*** ***, "** ************* **** ** ** **** ** ***** *** ************ in * **** ***** ***********?"

********** *** *** ******* ******** ** "*** ************* ********* ** prove ***** *** ************ **** ** * **** ***** ***********?" Unfortunately, **** ** **** *** ***. ***** ** ****** ** gain *** * *** ** **** ** *** ********** ** demonstrated ** ****** ********. *** ****, ****** ** **** ** potential **** ** ** ******* ** ****** *******.

**** *****, *** ******** * ****** ** **** ********* *** purchased ** ***-******** *************, **** ***** ** ***********. ******* **** science ******* *** *********** ************ **** **** ** ******** *****.

*******, * ***** **** ********* *** ***** *** **** ****** than ****** ** ******** ****** ********. *******, ** ***** **** some ****, *** ** ** **** ********* ** **** **********.

**** * *** *** ********** ***** “******* *** *****, ****** Integrators - **** ** **?”, ** ***** ******* ***, “***! Finally * ****** ***** *********** ****’* ***** ** *** ******.” Wrong! ** **** * **** * ******** ****** *** ********** bashing *******.

**** ****'* *********, ***** ********** *********** **** ** ******* *** scorn, ********** ** **** ** **** **** ** ***** ********* as ******* ** ***** ** **** *** **** ****** ** themselves, "***! **** *** ****. *'** ***** ** **** *****." In ******* ******, *** ******** *********** ****** **** ********* ***, or ** ** **** * ****** ** * *** *** apples ******* *** ***** *****?

*********,

*** ****** **********

****** **********, ** *** *** **** ****** *** *** ***********. In ** **********, *********** **** ** *** ** *** **** of ******* (**** **** ***** ** ********* **********) ***** *********** tend ** *** ** *** **** ** ****** (***'* *** in **** ******* *** ******* **** ** **** ** **** will ****).

* ***** **’* ********* **** **** *********** *** *********** ** better ******* *** *** ***** ** ****** ** **** *** realistic ************ *** ***** ******** *******. *******, **** ****** ** a *********** ****** (**** ********* ** *** **** **** ***** to ** ********). ** ******, *** ***** ************ *** **** is **** **** **** ** ******* ********** ********* **** ********** is ********* *** **** *** ************ *** *********** ***. ** the **** **** ******** ** * **** ********** ******* **** a **** **********, **** *** ***** **** **** ***** *** keep **** ***** ****** (“** **** ******** ****, ** *** person ******** *******.” ***. **:**). **** ****** **** ** *** best ******** ******** *** *** *** ****.

**** *** *** ***** **** ** *****:

*.) *** ** *** ******** *** “****” *********** *** ***********? I ***** ****** **** **** ************* *** ********** **** **** that. **** ** ** **** *** ****** ****** ********** ** the ******** ** *** ***** ******* ** ******** *************, (*** many ***-** ****** **** ***** ***** ** ****? *** **** non-AV ****** **** ***** ***-*?), ** *** ***** ** **** beneficial ** ****** ** ******* ************* ******** ************* ******** **** other. * ****** ******* ** ****, ************* *********** *** *********** can **** ******** *** ********* ** *** ***** *** ********.

*.) *** *** *** *** ************* ** **** ******* *** users’ ***** **** ******* *******, (***** ******* **** *** ******* end **** *** *** ****** **********)? ****’* * ***** ****** battle. * ******* **** *** ****** ** **, *** ***’* envy *** *** **. **********, ************* *** ***** ** ******** to **** ******** ********* ****** ** **** ** ***** ** no *********** ******** ** ***** ** (“********” ******* **** ******). Calling **** *** ** ********** * *****. *******/********* **** ** also **** ********** ** **** ******* **** ******* ** ************* security ************* ** *********** **** *** *****, “**, ****’* ********* BS. ** ***’* ** ****.” (** ******, ** *****’* **** when ******* ************* **** ** ****** ****-**** ********* ***** * small *** ***** ***** ** ***********.)

**** (*********) ******,

*** ****** **********

"** ******, ** *****’* **** **** ******* ************* **** ** almost ****-**** ********* ***** * ***** *** ***** ***** ** integrators."

***** ** ******* ***** ****** *****, *****? ;-)

**** *** ****, *** **** ** ***** *** **** ** that ********.